No Data
BeiGene Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results.
BeiGene Affirms FY2025 Sales Guidance of $4.90B-$5.30B Vs $36.54B Est
BeiGene Q1 Adj. EPS $1.22 Beats $(0.74) Estimate, Sales $1.12B Miss $8.09B Estimate
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
Hong Kong stock morning report｜A press conference on financial policies to stabilize the market will be held. The three major US stock indices closed lower while Chinese concept stocks strengthened against the trend.
① The USA's trade deficit reached an all-time high in March. The trade negotiations between the USA and Europe have encountered obstacles. Trump said that the USA does not need to sign a trade agreement. ② The State Council Information Office will hold a press conference to introduce financial policies to stabilize the market. ③ Treasury Secretary Lan Foan expressed confidence in achieving the growth target of around 5% by 2025. ④ The three major US stock indexes collectively closed lower, while many China Concept Stocks rose against the trend. ⑤ International Gold and Crude Oil Product futures rose by more than 3%.
BeiGene Q1 2025 Earnings Preview
